Pediatric blood & cancer
-
To evaluate the efficacy of interstitial brachytherapy (BRT) in children undergoing combined modality treatment for soft tissue sarcomas (STS). ⋯ Interstitial BRT with or without EBRT appears to result in satisfactory outcome in children with STS. Radical BRT alone, when used judiciously in select groups of children, results in excellent local control and functional outcome with reduced treatment-related morbidity.
-
Pediatric blood & cancer · Sep 2007
Multicenter StudyRisk factors for extraocular relapse following enucleation after failure of chemoreduction in retinoblastoma.
To assess the outcome and determine risk factors for extraocular relapse in patients with retinoblastoma who had been enucleated after failure of chemoreduction. ⋯ The risk of extraocular relapse is low after enucleation following failure of chemoreduction. Patients who underwent bilateral enucleation and those with scleral invasion are at higher risk of extraocular relapse.
-
Pediatric blood & cancer · Sep 2007
Factors associated with health-related quality of life in pediatric cancer survivors.
Childhood cancer survivors are at risk for late effects of disease and treatment that may be attributed to multiple causes. This study describes health-related quality of life (HRQOL) in childhood cancer survivors and identifies factors related to poor quality of life outcomes. ⋯ Long-term follow-up clinics for childhood cancer survivors are in a unique position to monitor HRQOL over time. Factors associated with poorer HRQOL include fatigue, ethnic minority status, a brain tumor diagnosis, and more severe late effects. Future studies need to clarify relationships between ethnicity, socioeconomic status (SES), and HRQOL in cancer survivors.
-
Pediatric blood & cancer · Aug 2007
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
To determine prognostic factors for local control in the radiotherapeutic management of non-metastatic Ewing sarcoma. ⋯ Radiotherapy dose was found to influence local control in ES. In particular, patients who received RT doses >or=49 Gy for tumor size